share_log

Adial Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Newman James W. Jr.

SEC ·  Mar 28 06:25
Summary by Futu AI
James W. Newman Jr., a reporting person for Adial Pharmaceuticals, Inc. (ADIL), has engaged in a transaction involving the company's stock. The action took place on March 25, 2024. However, the announcement did not disclose the nature of the transaction, including the action type, status, number of shares involved, transaction price, or the resulting number of shares held after the action. Without these details, the total value of the shares cannot be determined. The relationship of Newman to the issuer was also not specified in the provided information.
James W. Newman Jr., a reporting person for Adial Pharmaceuticals, Inc. (ADIL), has engaged in a transaction involving the company's stock. The action took place on March 25, 2024. However, the announcement did not disclose the nature of the transaction, including the action type, status, number of shares involved, transaction price, or the resulting number of shares held after the action. Without these details, the total value of the shares cannot be determined. The relationship of Newman to the issuer was also not specified in the provided information.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.